Melissa L Perreault

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5160358/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Indigenous Lens on Priorities for the Canadian Brain Research Strategy. Canadian Journal of Neurological Sciences, 2023, 50, 96-98.	0.5	4
2	GSK-3β Disrupts Neuronal Oscillatory Function to Inhibit Learning and Memory in Male Rats. Cellular and Molecular Neurobiology, 2022, 42, 1341-1353.	3.3	10
3	Cannabis Vapor Exposure Alters Neural Circuit Oscillatory Activity in a Neurodevelopmental Model of Schizophrenia: Exploring the Differential Impact of Cannabis Constituents. Schizophrenia Bulletin Open, 2022, 3, sgab052.	1.7	8
4	Sex differences in innate and adaptive neural oscillatory patterns link resilience and susceptibility to chronic stress in rats. Journal of Psychiatry and Neuroscience, 2021, 46, E258-E270.	2.4	16
5	Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 5511.	4.1	1
6	The Antidepressant-Like and Analgesic Effects of Kratom Alkaloids are accompanied by Changes in Low Frequency Oscillations but not ΔFosB Accumulation. Frontiers in Pharmacology, 2021, 12, 696461.	3.5	5
7	Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders. Brain Sciences, 2021, 11, 1199.	2.3	35
8	Glycogen Synthase Kinase-3: A Focal Point for Advancing Pathogenic Inflammation in Depression. Cells, 2021, 10, 2270.	4.1	5
9	Sex differences in neuronal systems function and behaviour: beyond a single diagnosis in autism spectrum disorders. Translational Psychiatry, 2021, 11, 625.	4.8	11
10	Transient Dose-dependent Effects of Ketamine on Neural Oscillatory Activity in Wistar-Kyoto Rats. Neuroscience, 2020, 441, 161-175.	2.3	14
11	Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. Biology of Sex Differences, 2020, 11, 8.	4.1	49
12	Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?. Pharmacological Research, 2020, 157, 104819.	7.1	13
13	Acute mitragynine administration suppresses cortical oscillatory power and systems theta coherence in rats. Journal of Psychopharmacology, 2020, 34, 759-770.	4.0	6
14	Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. Neuroscience Letters, 2019, 711, 134404.	2.1	9
15	Hormonal regulation of circuit function: sex, systems and depression. Biology of Sex Differences, 2019, 10, 12.	4.1	29
16	Extended Attenuation of Corticostriatal Power and Coherence after Acute Exposure to Vapourized Δ9-Tetrahydrocannabinol in Rats. Canadian Journal of Addiction, 2019, 10, 60-66.	0.4	9
17	Pathogenic Feed-Forward Mechanisms in Alzheimer's and Parkinson's Disease Converge on GSK-3. Brain Plasticity, 2018, 4, 151-167.	3.5	19
18	Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus. Frontiers in Aging Neuroscience, 2018, 9, 434.	3.4	20

#	Article	IF	CITATIONS
19	The atypical dopamine receptor agonist <scp>SKF</scp> 83959 enhances hippocampal and prefrontal cortical neuronal network activity in a rat model of cognitive dysfunction. European Journal of Neuroscience, 2017, 46, 2015-2025.	2.6	6
20	Activation of Dopamine D1-D2 Receptor Complex Attenuates Cocaine Reward and Reinstatement of Cocaine-Seeking through Inhibition of DARPP-32, ERK, and ΔFosB. Frontiers in Pharmacology, 2017, 8, 924.	3.5	55
21	Disruption of a dopamine receptor complex amplifies the actions of cocaine. European Neuropsychopharmacology, 2016, 26, 1366-1377.	0.7	36
22	Rapid anti-depressant and anxiolytic actions following dopamine D1–D2 receptor heteromer inactivation. European Neuropsychopharmacology, 2015, 25, 2437-2448.	0.7	40
23	Regulation of c-fos expression by the dopamine D1-D2 receptor heteromer. Neuroscience, 2015, 285, 194-203.	2.3	23
24	The dopamine D1–D2 receptor heteromer exerts a tonic inhibitory effect on the expression of amphetamine-induced locomotor sensitization. Pharmacology Biochemistry and Behavior, 2015, 128, 33-40.	2.9	22
25	Dopamine D ₁ -D ₂ Receptor Heteromer Regulates Signaling Cascades Involved in Addiction: Potential Relevance to Adolescent Drug Susceptibility. Developmental Neuroscience, 2014, 36, 287-296.	2.0	19
26	A peptide targeting an interaction interface disrupts the dopamine D1â€D2 receptor heteromer to block signaling and function <i>in vitro</i> and <i>in vivo:</i> effective selective antagonism. FASEB Journal, 2014, 28, 4806-4820.	0.5	45
27	Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevance. Neuropsychopharmacology, 2014, 39, 156-168.	5.4	133
28	Enhanced Brain-Derived Neurotrophic Factor Signaling in the Nucleus Accumbens of Juvenile Rats. Developmental Neuroscience, 2013, 35, 384-395.	2.0	9
29	A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. International Journal of Neuropsychopharmacology, 2013, 16, 477-483.	2.1	54
30	Reduced striatal dopamine D1–D2 receptor heteromer expression and behavioural subsensitivity in juvenile rats. Neuroscience, 2012, 225, 130-139.	2.3	19
31	Dopamine D1–D2 Receptor Heteromer in Dual Phenotype GABA/Glutamate-Coexpressing Striatal Medium Spiny Neurons: Regulation of BDNF, GAD67 and VGLUT1/2. PLoS ONE, 2012, 7, e33348.	2.5	54
32	Dopamine Receptor Homooligomers and Heterooligomers in Schizophrenia. CNS Neuroscience and Therapeutics, 2011, 17, 52-57.	3.9	29
33	The Dopamine D1–D2 Receptor Heteromer in Striatal Medium Spiny Neurons: Evidence for a Third Distinct Neuronal Pathway in Basal Ganglia. Frontiers in Neuroanatomy, 2011, 5, 31.	1.7	109
34	The Dopamine D1-D2 Receptor Heteromer Localizes in Dynorphin/Enkephalin Neurons. Journal of Biological Chemistry, 2010, 285, 36625-36634.	3.4	162
35	Regulation of Dopamine Receptor Trafficking and Responsiveness. , 2010, , 193-217.		1
36	Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21377-21382.	7.1	232

#	Article	IF	CITATIONS
37	Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD) Behavioral Neuroscience, 2007, 121, 976-991.	1.2	29
38	Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats. Psychopharmacology, 2007, 194, 485-496.	3.1	20
39	Development and temporal organization of compulsive checking induced by repeated injections of the dopamine agonist quinpirole in an animal model of obsessive-compulsive disorder. Behavioural Brain Research, 2006, 169, 303-311.	2.2	31
40	Psychosis pathways converge via D2High dopamine receptors. Synapse, 2006, 60, 319-346.	1.2	298
41	Kappa-Opioid Agonist U69593 Potentiates Locomotor Sensitization to the D2/D3 Agonist Quinpirole: Pre- and Postsynaptic Mechanisms. Neuropsychopharmacology, 2006, 31, 1967-1981.	5.4	27
42	Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3513-3518.	7.1	335
43	Transgenic growth hormone mice exposed to lifetime constant illumination: gender-specific effects. Canadian Journal of Zoology, 2004, 82, 950-965.	1.0	2
44	Thermoregulation of transgenic growth hormone mice. Canadian Journal of Zoology, 2004, 82, 934-949.	1.0	5